Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050
Keros to Present at Leerink Partners 2024 Global Biopharma Conference
LEXINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros or the Company) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and...
Keros To Present at Pulmonary Vascular Research Institute 2024 Annual Congress
LEXINGTON, Mass., Jan. 09, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (œKeros or œwe) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
Keros commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial to evaluate single and multiple ascending doses of KER-065 in healthy volunteers Keros expects to report...
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...
LEXINGTON, Mass., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (Keros or we) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing...
KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burdenDurable clinical responses were associated with improvements in...
LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (œKeros) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel...